article thumbnail

Bad Notes on Venture Capital

Both Sides of the Table

At an accelerator … Me: Raising convertible notes as a seed round is one of the biggest disservices our industry has done to entrepreneurs since 2001-2003 when there were “full ratchets” and “multiple liquidation preferences” – the most hostile terms anybody found in term sheets 10 years ago. Employment.

article thumbnail

Bad Notes on VC

Gust

Me: Raising convertible notes as a seed round is one of the biggest disservices our industry has done to entrepreneurs since 2001-2003 when there were “full ratchets” and “multiple liquidation preferences” – the most hostile terms anybody found in term sheets 10 years ago. At an accelerator …. Not in my experience. A few M&A transactions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Term-sheets and Valuations: Thinking about Negotiations - Startups.

Tim Keane

  A full ratchet anti-dilution clause is very unfriendly to entrepreneurs; it requires them to make up the entire difference in price from their own holdings.   However, I assume that the proposed business solves a real problem that people are willing to pay for and that it may be lest costly, more efficient, and IP-protected. [5]

article thumbnail

Thoughts on WeWork

This is going to be BIG.

Sometimes they have various ratchets and other bells and whistles that protect their downside further, like when Square IPO’d. The IP transfer from the founder, his family’s underlying interest in some of the real estate—it might end up being all square, but it just gives people pause.

article thumbnail

Out of the Crisis #5, ANA Therapeutics: a possible COVID-19 treatment and prophylactic

Startup Lessons Learned

And while I didn't spend a great deal of time in research, I somehow pivoted into IP licensing, which led me to meet Nadja and we founded YourChoice Therapeutics together, and that's what led to the genesis of ANA Therapeutics. And often what we're seeing in these hydroxychloroquine studies is a big ratcheting of a typical dose.